Loading stock data…
HRTX
$0.40-0.05 (-10.74%)
Market ClosedLast close Jun 9
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Heron Therapeutics, Inc. in the Healthcare sector is trading at $0.40 with a market capitalization of $165M. Wall Street consensus targets $3.00 (2 analysts), implying a +640.9% move over the next 12 months. The stock is currently near its 52-week low of $0.40, remaining 64.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 17 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +640.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 17) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.40
Potential Downside
0%
Whystock Fair Value$0.40
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Buy
Mean target$3.00+640.9%
Range$2.00 – $4.00
Fundamentals
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, w...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$164.69M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-140.90%
Volume
Today's trading volume
4.36M
Recent News
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today?
The selloff highlighted the risks facing smaller companies operating in biotechnology and emerging technology.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks declined late Tuesday afternoon, with the NYSE Healthcare Index decreasing 0.8% an
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?
We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Heron Therapeutics, Inc. (NASDAQ:HRTX) is another of the best penny stocks on this list. TheFly reported on May 11 that HRTX saw its price target reduced to $4 from $6 while the Buy rating was reiterated in a recent research […]
Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges
Heron Therapeutics Inc (HRTX) reports strong recovery and strategic expansions despite weather-related setbacks and competitive pressures.
Heron Therapeutics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Heron Therapeutics, Inc.'s Q1 2026 earnings call